Daratumumab

Drug Profile

Daratumumab

Alternative Names: DARZALEX; Humanised anti-CD38 monoclonal antibody; HuMax-CD38; HuMax®-CD38 - Genmab; JNJ-54767414

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Genmab
  • Developer Boston Medical Center; Bristol-Myers Squibb; Genentech; Genmab; Janssen Biotech; Janssen Research & Development
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD38 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Multiple myeloma; Mantle-cell lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Prostate cancer; T cell lymphoma
  • Phase I/II Amyloid light-chain amyloidosis; Non-small cell lung cancer; Solid tumours
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 17 Jul 2017 Merck Sharp & Dohme plans the phase II KEYNOTE-668 trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Canada, France, Israel, Norway, Spain and Sweden (IV) (NCT03221634)
  • 01 Jul 2017 Janssen initiates enrolment in a phase II trial in Multiple myeloma (Combination therapy, Newly diagnosed) in USA (IV) (NCT03004287)
  • 16 Jun 2017 The US FDA approves daratumumab for use in Multiple myeloma (Combination therapy, Second line therapy or greater) (In combination with pomalidomide and dexamethasone) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top